Opus Genetics, Inc.

XNAS

Last traded price · USD

$4.22

−1.17%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:24 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $4.27
Volume: 1,398
Day's high: —
Day's low: —

In brief

Opus Genetics, Inc. is a US-listed company listed on Nasdaq, valued at about $351M.
Its shares closed at $4.27 on 4 Nov 2026, up 96.8% over the past year.
From India you can buy IRD in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Opus Genetics, Inc. (IRD) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole IRD share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade IRD options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY over 1 year
1 month: −2.5% (SPY −1.6%). 3 months: +13.0% (SPY −0.4%). 1 year: +96.8% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IRD, SPY · as of 4 Nov 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $4.27 was 4.3% below its 50-day average ($4.46) and 1.4% above its 200-day average ($4.21). It has closed above the 200-day for 1 session, since 4 Nov 2026.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
7.4 days to cover short interest
13.3M shares were sold short at the 15 Oct 2026 settlement, 16.1% of the 82.6M shares outstanding; covering them would take 7.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
53% of the way up its 52-week range
Closed at $4.27 on 4 Nov 2026: 35.1% below the 52-week high of $6.58 (11 Sep 2026) and 151.2% above the low of $1.70 (18 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−2.5%

6 months−18.8%

1 year+96.8%

5 years—

Newswire

About

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

Website

Notable moves

September 9, 2026
+32.03%
March 18, 2025
+17.88%
December 19, 2024
+18.93%

Opus Genetics, Inc.

XNAS

Last traded price · USD

$4.22

−1.17%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:24 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $4.27
Volume: 1,398
Day's high: —
Day's low: —

In brief

Opus Genetics, Inc. is a US-listed company listed on Nasdaq, valued at about $351M.
Its shares closed at $4.27 on 4 Nov 2026, up 96.8% over the past year.
From India you can buy IRD in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Opus Genetics, Inc. (IRD) shares from India?

Do I need the price of a whole IRD share to invest?

How much can I invest in US stocks in a year?

Can I trade IRD options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY over 1 year
1 month: −2.5% (SPY −1.6%). 3 months: +13.0% (SPY −0.4%). 1 year: +96.8% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IRD, SPY · as of 4 Nov 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $4.27 was 4.3% below its 50-day average ($4.46) and 1.4% above its 200-day average ($4.21). It has closed above the 200-day for 1 session, since 4 Nov 2026.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
7.4 days to cover short interest
13.3M shares were sold short at the 15 Oct 2026 settlement, 16.1% of the 82.6M shares outstanding; covering them would take 7.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
53% of the way up its 52-week range
Closed at $4.27 on 4 Nov 2026: 35.1% below the 52-week high of $6.58 (11 Sep 2026) and 151.2% above the low of $1.70 (18 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−2.5%

6 months−18.8%

1 year+96.8%

5 years—

Newswire

About

Website

Notable moves

September 9, 2026
+32.03%
March 18, 2025
+17.88%
December 19, 2024
+18.93%

Opus Genetics, Inc.

Opus Genetics, Inc. in brief

Ahead of SPY over 1 year

Below its 50-day average, above its 200-day

7.4 days to cover short interest

53% of the way up its 52-week range

Opus Genetics, Inc.

Opus Genetics, Inc. in brief

Ahead of SPY over 1 year

Below its 50-day average, above its 200-day

7.4 days to cover short interest

53% of the way up its 52-week range